PTC Therapeutics, Inc. (PTCT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Matthew B. Klein F.A.C.S., M.D., M.S. | CEO & Director | 995.4k | -- | 1973 |
| Dr. Stuart W. Peltz Ph.D. | Co-Founder, Senior Consultant & Member of Scientific Advisory Board | 1.54M | -- | 1960 |
| Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 145k | -- | 1946 |
| Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 829.97k | -- | 1967 |
| Mr. Eric Pauwels | Chief Business Officer | 847.67k | -- | 1961 |
| Mr. Pierre Gravier M.S. | Chief Financial Officer | -- | -- | 1986 |
| Ms. Christine Utter | Senior VP, Chief Accounting Officer & Head of People Services | 595.54k | 995.57k | 1978 |
| Alex Kane | Investor Relations Officer | -- | -- | -- |
| Mr. Mark Elliott Boulding | Executive VP & Chief Legal Officer | 824.09k | 355.34k | 1961 |
| Ms. Jane Baj | Vice President of Corporate Communications | -- | -- | -- |
PTC Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 988
Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Corporate Governance
Recent Events
- Apr 26, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 25, 202410-Q: Periodic Financial ReportsSee Full Filing
- Feb 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 25, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 24, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing